Analyst consensus rating
Rein Therapeutics Analyst Rating: none
Direct answer
Rein Therapeutics's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.00.
Forecast evidence checked October 19, 2026.
Get free Rein Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.59
- Average price target
- $6.00
- High price target
- $8.00
- Low price target
- $4.00
- Low target gap
- +577.6%
- Target upside
- +916.4%
- High target gap
- +1,255.2%
- Target range width
- 677.6%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Rein Therapeutics?
Rein Therapeutics has a verified none consensus. The same dataset has an average price target of $6.00.
How far are Rein Therapeutics's low and high targets from the recorded price?
The low target implies +577.6%, while the high target implies +1,255.2%.
How many analysts are included in Rein Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Rein Therapeutics's target upside or downside calculated?
The average target of $6.00 is divided by the recorded price of $0.59, then one is subtracted to produce +916.4%. This does not guarantee a future return.
When was Rein Therapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.